Lett E, Klopfenstein C, Klein J P, Schöller M, Wachsmann D
Unité 392, Institut National de la Santé et de la Recherche Médicale, Faculté de Pharmacie, Illkirch, France.
Infect Immun. 1995 Jul;63(7):2645-51. doi: 10.1128/iai.63.7.2645-2651.1995.
In this study we investigated the mucosal and systemic responses to two T-cell-independent polysaccharides, a serogroup f polysaccharide (formed of rhamnose glucose polymers [RGPs]) from Streptococcus mutans OMZ 175 and a mannan from Saccharomyces cerevisiae, covalently conjugated either to a linear peptide (peptide 3) or to a multiple-antigen peptide (MAP), both derived from S. mutans protein SR, an adhesin of the I/II protein antigen family of oral streptococci. Peptide 3 and MAP, which contained at least one B- and one T-cell epitope, were tested as carriers for the polysaccharides and as protective immunogens. Intragastric intubation of rats with the conjugates (RGPs-peptide 3, RGPs-MAP, mannan-peptide 3, and mannan-MAP) associated with liposomes produced salivary immunoglobulin A (IgA) antibodies which reacted with RGPs or mannan, peptide 3 or MAP, protein SR, and S. mutans or S. cerevisiae cells. Administration of conjugate boosters to the animals showed that both carriers conjugated to the polysaccharides were able to induce, in immunized animals, a salivary antipolysaccharide IgA memory. In contrast, animals primed and challenged with unconjugated polysaccharide showed no anamnestic response. Rats orally immunized with the conjugates also developed systemic primary antipolysaccharide and antipeptide IgM antibody responses which were characterized by a switch from IgM to IgG during the course of the secondary response. Data presented here demonstrated that both peptide 3 and the MAP construct can act as good carriers for orally administered polysaccharides. Unexpectedly, the use of a MAP did not further improve the immunogenicity of polysaccharides at the mucosal level; nevertheless, such a construct should be of great interest in overcoming the problem of genetic restriction induced by linear peptides.
在本研究中,我们调查了对两种非T细胞依赖性多糖的黏膜和全身反应,一种是变形链球菌OMZ 175的血清群f多糖(由鼠李糖葡萄糖聚合物[RGP]组成),另一种是酿酒酵母的甘露聚糖,它们分别与源自口腔链球菌I/II蛋白抗原家族的黏附素变形链球菌蛋白SR的线性肽(肽3)或多抗原肽(MAP)共价偶联。肽3和MAP含有至少一个B细胞和一个T细胞表位,被用作多糖的载体和保护性免疫原进行测试。将与脂质体相关的偶联物(RGP - 肽3、RGP - MAP、甘露聚糖 - 肽3和甘露聚糖 - MAP)经胃内插管给予大鼠后,产生了唾液免疫球蛋白A(IgA)抗体,该抗体可与RGP或甘露聚糖、肽3或MAP、蛋白SR以及变形链球菌或酿酒酵母细胞发生反应。给动物注射偶联物加强剂表明,与多糖偶联的两种载体都能够在免疫动物中诱导唾液抗多糖IgA记忆。相比之下,用未偶联的多糖进行初次免疫和再次攻击的动物未表现出回忆反应。经口用偶联物免疫的大鼠还产生了全身性的原发性抗多糖和抗肽IgM抗体反应,其特征是在二次反应过程中从IgM转换为IgG。此处呈现的数据表明,肽3和MAP构建体都可作为口服多糖的良好载体。出乎意料的是,MAP的使用并未在黏膜水平进一步提高多糖的免疫原性;然而,这样的构建体在克服线性肽诱导的基因限制问题方面应该会引起极大的兴趣。